For example, overexpression of E2F1 enhanced the resistance of paclitaxel combined with DDP and accelerated gastric cancer cell proliferation, while silenced E2F1 promoted the treatment efficacy of paclitaxel combined with DDP [16]. Here, E2F1 is linked to gastric cancer.